Linden Capital Partners

Linden Capital Partners is a Chicago-based private equity firm that invests exclusively in healthcare and life sciences, executing leveraged buyouts in middle-market companies. Within healthcare, the firm concentrates on Medical Devices and MedTech alongside Pharma and Therapeutics, two capital-intensive sub-sectors where deep operating expertise and regulatory understanding matter. AI is not a stated thematic focus.

Linden writes checks of $25M and above at the growth stage, with a buyout orientation. The firm is US-headquartered and primarily focuses on North American healthcare assets. Named portfolio companies and team members are not included in the data available here; founders evaluating a fit should review the firm’s deal history directly to gauge recent activity in their specific sub-vertical.

For AI-native founders, Linden is unlikely to be the right investor unless your company is a profitable, scaled medtech or pharma services business considering a control transaction. Pre-commercial companies, even in medical devices, will generally find Linden’s stage and check size mismatched. Approach when you have FDA clearance, established revenue, and a strategic case for either a recap, an exit to a financial sponsor, or a platform-and-add-on roll-up. The exclusively healthcare focus does mean diligence conversations will be substantive on regulatory and clinical detail.